Lentigen Technology, Inc.
Miltenyi Biotec acquired Lentigen Technology in 2014. In 2021, the lentiviral vector manufacturing business of Lentigen Technology was integrated into the new division Miltenyi Bioindustry to complete Miltenyi Biotec’s CDMO services.
Facts and figures
Focus
Clinical development, lentiviral vector R&D
Location
Gaithersburg, MD, USA
Number of employees
~ 50
General information
Lentigen Technology focused on the development and commercialization of breakthrough treatments for human disease. Lentiviral vectors (LV), the company's technology platform, are widely recognized by the scientific community as the most efficient method for delivery of genetic information into cells to reprogram their function.
Expertise and technology
The Lentigen Technology team has been a leader in lentiviral vector development and manufacturing, offering end-to-end solutions from preclinical development and vector design to GMP production for a long time. As the discovery engine for our customers’ CAR and TCR therapeutic pipelines, the team in Gaithersburg supports the development of innovative cell therapies targeting rare indications and diseases with high unmet medical need, including difficult-to-treat cancers and autoimmune conditions. Its scalable, high-titer lentiviral platform also powers Miltenyi Biotec’s commercial off-the-shelf therapeutic vectors, accelerating the availability of advanced treatments for patients with limited options.
Milestones
- 2004 – Founding of Lentigen Technology
- 2006 – First-in-man lentiviral vector clinical trial (HIV indication, successful demonstration of safety)
- 2009 – First patients treated with Lentigen vector
- 2012 – First client adherent GMP batch Lentigen vector
- 2014 – Produced a CD22 vector used clinically for the first time
- 2016 – CliniMACS Prodigy® T cell engineering (TCE) process established
- 2017 – First patients treated with Lentigen tandem vector and CliniMACS Prodigy
- 2017 – First client 50L GMP serum-free suspension batch
- 2019 – Production of the 1,000th batch
- 2020 – First client 200L GMP serum-free suspension batch
- 2021 – Integration of vector manufacturing business into Miltenyi Bioindustry
- 2022 – First client Process Performance Qualification (PPQ) batches in support of commercial manufacturing
- 2024 – Manufacturing of lentiviral vectors for FDA-approved TCR T-cell therapy TECELRA®
Open positions
Explore new job opportunities at our site in Gaithersburg.
Miltenyi Biotec, Inc.
1201 Clopper Road, Gaithersburg, MD 20878, USA
Phone +1 530 888 8871
macsus@miltenyi.com